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Cyclosporin A  (CsA) ~ is a potent reversible immunosuppressive agent which is 
able to suppress allograft rejection and acute allogeneic graft-versus-host disease 
(GVHD)  (1-7).  Although  CsA  dramatically  improves survival  after allogeneic 
marrow transplantation, rats treated with a short course of CsA develop delayed 
onset  GVHD  after  CsA  withdrawal.  This  paper presents  new  evidence  which 
indicates  that  GVHD  may  develop  upon  CsA  withdrawal  following  not  only 
allogeneic but also syngeneic and even autologous bone marrow reconstitution. 
Materials and  Methods 
Rats.  Lewis female RT1 ~ rats,  6-8  wk  old,  were  purchased  from Harlan  Sprague 
Dawley, Inc., Indianapolis, IN. 
Radiation.  Lewis rats were irradiated on day -1  (1,020 rad) at 120 rad/min from a 
dual  source  Cs ~3~  small  animal  irradiator  (Atomic  Energy  of Canada  Ltd.,  Ottawa, 
Ontario). Leg-shielded rats were then anesthetized with chloral hydrate, their right tibias 
shielded with a lead doughnut  1.5  cm thick and 2.5 cm long, and irradiated with  1,020 
rad. 
Marrow  Transplantation.  Donor  marrow  from  tibias,  femurs,  and  humeri  was  sus- 
7  pended at 6  ×  10  nucleated cells/ml in  Hanks' solution supplemented with  50  U/ml 
penicillin and 50 ng/ml streptomycin. On day 0 rats received 1 ml via the tail vein. 
Antibiotics.  Rats received medicated drinking water supplemented with bactrim, neo- 
mycin, and polymyxin B and were given 2.5 mg/kg gentamycin per day subcutaneously 
for  20  d.  Rats  that  developed  overt  clinical  infections  were  routinely  sacrificed  and 
excluded from the study. 
Cyclosporin A.  CsA was the generous gift of Sandoz, Inc., Hanover, NJ. Emulphor EL- 
620 was obtained from GAF Corp., New York. Powdered CsA was dissolved in absolute 
ethanol, added to emulphor, and mixed with water to yield a final emulphor concentration 
of 5%. Rats were weighed daily and received 1 ml/100 g body weight per day subcuta- 
neously from day 0 to 40 or as indicated. 
Assessment of GVHD.  Rats were examined daily for signs of clinical GVHD such as red 
ears, dermatitis, or diarrhea.  Skin biopsies were taken at frequent intervals. When rats 
developed severe clinical GVHD characterized by weight loss, hunched appearance, and 
extensive dermatitis they were sacrificed and autopsied. Previously described criteria were 
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FIGURE  1.  Grade II acute GVHD in a CsA-treated rat after autologous reconsitution. Note 
extensive mononuclear epidermal infiltrate, x  310. 
FIGURE 2.  Syngeneic GVHD  in  the tongue of a  CsA-treated Lewis chimera. There is a 
mucosal and submucosal mononuclear infiltrate with islands of mucosal destruction, x  .510. GLAZIER  ET  AL. 
FIGURE 3.  Esophagus from a rat with syngeneic GVHD with extensive lymphocyte exocytosis 
and destruction of basal mucosa. ×  310. 
FIGURE 4.  Hepatic syngeneic GVHD. Note extensive mononuc]ear infiltrate in portal triad. 
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TABLE  I 
GVHD in Cyclosporin A-treated Syngeneic Chimeras 
Fraction with grade II 
CsA dose  Days of treatment  GVHD 
mg/kg/d 
0  20  1/64" 
2.5  2O  O/3 
7.5  20  8/13 
7.5  4O  21/22 
15  20  9/14 
15  40  17/20 
25  20  3/14 
25  40  8/8 
40  20  2/6 
Lethally irradiated Lewis rats were reconstituted with syngeneic marrow 
and treated with CsA at the dose indicated for either 20 or 40 d beginning 
on day 0. Results pooled from three experiments. 
* Control group represents data pooled from seven experiments. 
used for the histological documentation of GVHD (8). Grade II acute GVHD was defined 
by the presence of lymphocytic exocytosis, epidermal destruction with vacuolar changes 
of the basal layer, and dyskeratotic cells. 
Adoptive Transfer of  GVHD.  Donor spleens were suspended in Hanks' solution by gently 
pressing the spleens through a stainless  steel screen. GVHD was adoptively transferred 
with 6 ×  107 marrow cells and 108 spleen cells given intravenously to irradiated syngeneic 
rats. In some experiments marrow and spleen cells were pooled from donors with GVHD. 
Results 
Syngeneic GVHD.  Lethally irradiated Lewis rats were reconstituted with syn- 
geneic bone marrow and treated with control diluent or CsA. Syngeneic radiation 
chimeras not treated with CsA as a  rule did not develop clinical or histological 
GVHD.  In seven independent syngeneic transplants only 1 of 64 chimeras not 
treated with CsA developed GVHD. At autopsy this rat had intense sialodacroad- 
enitis suggestive of an underlying coronavirus infection. In contrast 68 of 97 rats 
reconstituted with syngeneic marrow and treated with CsA at 7.5-40 mg/kg per 
day for 20-40  d  developed clinical and histological GVHD (P <  0.001)  (Table 
I). GVHD was not seen while the rats were receiving CsA.  Erythematous ears, 
dermatitis, hair loss, diarrhea, and weight loss were observed in most rats 12-40 
d  after the CsA was stopped.  Characteristic histological lesions of GVHD were 
seen in the skin, tongue, esophagus, and liver (Fig.  1-4).  Pronounced lymphoid 
atrophy  of the  thymus,  spleen,  and  lymph  nodes  was  observed  in  syngeneic 
chimeras that developed GVHD after a  20-d course of CsA. Lymphoid atrophy 
was less striking in  rats which developed  GVHD after 40  d  of post-transplant 
CsA  treatment.  Large  numbers  of lymphoblasts were  observed  in  the  lymph 
nodes of these rats at day 55. 
Autologous  GVHD.  It  might be  argued  that  CsA merely amplifies a  GVHD 
response due to subtle genetic differences between "syngeneic rats". To test this 
hypothesis Lewis rats  were  irradiated with  1,020  rad,  shielding the right tibia 
with a  lead doughnut. Four out of four leg-shielded CsA-treated rats developed 
clinical and  histological acute  GVHD.  We  have  observed  no  GVHD  in  seven GLAZIER  ET  AL.  5 
untreated leg-shielded rats (Table II). 
Adoptive Transfer of Syngeneic and Autologous GVHD.  Table III shows the results 
of four independent adoptive transfer experiments. Syngeneic GVHD may be 
adoptively transferred with spleen cells and marrow to lethally irradiated synge- 
neic recipients. Unirradiated rats are resistant to the adoptive transfer of synge- 
neic GVHD.  Preliminary results  suggest  that  both  syngeneic and  autologous 
GVHD  is  mediated by T  cells.  The adoptive  transfer of both  syngeneic and 
autologous GVHD was prevented by treating the spleen cells with a potent rabbit 
anti-rat thymocyte serum (9)  and guinea pig complement. Complement alone 
did not interfere with the adoptive transfer of the GVHD. 
Normal rats are refractory to the adoptive transfer of syngeneic GVHD and 
normal untransplanted rats do not develop GVHD after CsA withdrawal (data 
not shown). 
These  results  suggest  that  normal  rats  possess  active  tolerance-maintaining 
mechanisms that prevent the development of autologous GVHD and the transfer 
of established  syngeneic GVHD.  Table  IV  shows  the  results  of an  adoptive 
transfer experiment in  which lethally irradiated  Lewis rats  were transplanted 
with Lewis marrow and syngeneic spleen cells from rats with GVHD. One group 
TABLE  II 
Autologous GVHD 
Fraction with histologically verified 
Treatment  clinical GVHD 
No CsA  0/7 
CsA  4/4 
Lewis rats were  irradiated (1,020 rad) with shielding of the right tibia. 
CsA-treated rats received 10 mg/kg/d  for 18 d. (P <  0.005). 
TABLE  III 
Adoptive Transfer of Syngeneic GVHD 
Pretreatment of secondary recipi-  Fraction of secondary recipients 
ent  with GVHD 
No radiation  0/5 
1,020 Rad  12/13 
l0  s spleen cells from CsA-treated rats with syngeneic GVHD were trans- 
ferred along with 6 x  107 syngeneic Lewis marrow cells. Data pooled from 
four independent experiments (P <  0.005). 
TABLE  IV 
Failure of Normal Spleen Cells to Prevent the Adoptive Transfer of Syngeneic GVHD 
Cells transplanted  Fraction with clini-  Fraction with grade 
cal GVHD  II acute GVHD  Onset day 
GVHD spleen plus normal marrow  3/3  3/3  12 
GVHD spleen plus normal marrow plus nor-  3/3  3/3  12 
mal spleen 
Lethally irradiated  Lewis rats were transplanted with 6  x  10  7 Lewis marrow cells and  l0  s  Lewis 
spleen cells from rats with syngeneic GVHD.  l0  s normal Lewis spleen cells were also given to some 
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TAnLE  V 
Failure of Normal Spleen Cells to Prevent the Development of GVHD in CsA-treated 
Syngeneic Chimeras 
CsA mg/kg/d  Fraction with clinical  Fraction with grade II 
Cells transplanted  for 40 d  GVHD  histological GVHD 
Marrow only  0  0/6  0/6 
Marrow and spleen  0  0/5  0/5 
Marrow only  7.5  13/16  15/16 
Marrow and spleen  7.5  11 /  12  12/12 
Marrow only  15  11/16  13/16 
Marrow and spleen  15  3/3  12/t 2 
Lewis rats were lethally irradiated and treated with CsA or control diluent from day 0 
to day 40. The rats were transplanted with 6 x  107 syngeneic Lewis marrow cells and 
10 s spleen cells as indicated above. 
also received an equal number of normal spleen cells. All rats developed grade 
II acute GVHD.  As shown in Table V  normal spleen cells also did not prevent 
the development of syngeneic GVHD when given at the time of marrow trans- 
plantation to CsA-treated syngeneic chimeras. 
Discussion 
The key observation presented in this paper is the consistent development of 
GVHD in CsA-treated rats after syngeneic or autologous bone marrow reconsti- 
tution, developing upon the discontinuation of CsA. Syngeneic GVHD may be 
adoptively transferred  to irradiated  but not normal syngeneic recipients. Syn- 
dromes similar to syngeneic and autologous GVHD  have  previously been  de- 
scribed in neonatally thymectomized mice (I 0) and in neonatal mice given large 
doses of staphylococcal  vaccines (11).  In addition  isolated  cases of GVHD  in 
patients receiving bone marrow  from identical twins have been reported (12, 
13).  The existence  of syngeneic and  autologous GVHD  provides compelling 
evidence that histocompatibility differences are not absolutely necessary for the 
development of GVHD. 
CsA at low concentration in vitro reversibly inhibits the proliferative response 
of primary mixed lymphocyte reactions and prevents the development of cyto- 
toxic T  cells (14, 15). CsA appears to interfere with both the production and the 
acquisition of responsiveness to T cell growth factor (16-18). In vivo CsA induces 
a state of profound immunosuppression and is able to reversibly suppress allograft 
rejection  and acute allogeneic  GVHD  (1-7).  The  mechanisms by  which CsA 
causes syngeneic GVHD are at present enigmatic and the mechanisms by which 
normal  rats  resist  the  adoptive  transfer  to  established  GVHD  remain  to  be 
identified. 
Summary 
Lethally irradiated rats treated with cyclosporin A (CsA) for 20-40 d develop 
classic graft-versus-host disease (GVHD)  when reconstituted with syngeneic or 
autologous bone marrow, upon discontinuation of CsA, whereas normal rats do 
not. Syngeneic GVHD may be transferred to irradiated but not normal syngeneic GLAZIER ET AL.  7 
recipients.  Normal  spleen  cells  fail  to  prevent  the  development  or  adoptive 
transfer of syngeneic GVHD. 
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